Immunologic properties of differentiated and undifferentiated mesenchymal stem cells derived from umbilical cord blood

Hj, Lee; Kang, Kyung‐Sun; Kang, Sun-Young; Kim, Hyung–Sik; Park, Se Jin; Lee, Seung Yong; Kim, Kwang-Dong; Lee, Hee-Chun; Park, Ji Kwon; Paik, Woon Ki; Lee, Lyon; Yeon, Seong-Chan

doi:10.4142/jvs.2016.17.3.289

Cited by 18 publications

(11 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, host-derived pro-inflammatory cytokines can impair the capability of MSCs to differentiate into bone, fat, and cartilage lineages [see ( 94 )]. However, even after MSCs have differentiated into chondrocytes, they can exert immunosuppressive effects ( 108 , 109 ).…”

Section: Mesenchymal Stem Cells As a Therapeutic Strategy For Frailtymentioning

confidence: 99%

Mesenchymal Stem Cell Therapy for Aging Frailty

2018

View full text Add to dashboard Cite

Chronic diseases and degenerative conditions are strongly linked with the geriatric syndrome of frailty and account for a disproportionate percentage of the health care budget. Frailty increases the risk of falls, hospitalization, institutionalization, disability, and death. By definition, frailty syndrome is characterized by declines in lean body mass, strength, endurance, balance, gait speed, activity and energy levels, and organ physiologic reserve. Collectively, these changes lead to the loss of homeostasis and capability to withstand stressors and resulting vulnerabilities. There is a strong link between frailty, inflammation, and the impaired ability to repair tissue injury due to decreases in endogenous stem cell production. Although exercise and nutritional supplementation provide benefit to frail patients, there are currently no specific therapies for frailty. Bone marrow-derived allogeneic mesenchymal stem cells (MSCs) provide therapeutic benefits in heart failure patients irrespective of age. MSCs contribute to cellular repair and tissue regeneration through their multilineage differentiation capacity, immunomodulatory, and anti-inflammatory effects, homing and migratory capacity to injury sites, and stimulatory effect on endogenous tissue progenitors. The advantages of using MSCs as a therapeutic strategy include standardization of isolation and culture expansion techniques and safety in allogeneic transplantation. Based on this evidence, we performed a randomized, double-blinded, dose-finding study in elderly, frail individuals and showed that intravenously delivered allogeneic MSCs are safe and produce significant improvements in physical performance measures and inflammatory biomarkers. We thus propose that frailty can be treated and the link between frailty and chronic inflammation offers a potential therapeutic target, addressable by cell therapy.

show abstract

Section: Mesenchymal Stem Cells As a Therapeutic Strategy For Frailtymentioning

confidence: 99%

Mesenchymal Stem Cell Therapy for Aging Frailty

2018

View full text Add to dashboard Cite

show abstract

“…Thus, allogeneic stem cells derived from healthy humans may be an alternative for treating ONFH. Interestingly, there is evidence for the accumulation of low-immunogenicity MSCs, which allows the MSCs to be transplanted between human leukocyte antigen (HLA)-incompatible individuals [ 34 ]. hUCMSCs may be a good candidate for this approach, because umbilical cord (UC) collection is easy and ethically feasible.…”

Section: Outcomes In Clinical Applicationsmentioning

confidence: 99%

Stem cell therapy for treating osteonecrosis of the femoral head: From clinical applications to related basic research

Lin

Liang

et al. 2018

Stem Cell Res Ther

View full text Add to dashboard Cite

Osteonecrosis of the femoral head (ONFH) is a refractory disease that is associated with collapse of the femoral head, with a risk of hip arthroplasty in younger populations. Thus, there has been an increased focus on early interventions for ONFH that aim to preserve the native articulation. Stem cell therapy is a promising treatment, and an increasing number of recent studies have focused on this topic. Many clinical studies have reported positive outcomes of stem cell therapy for the treatment of ONFH. To improve the therapeutic effects of this approach, many related basic research studies have also been performed. However, some issues must be further explored, such as the appropriate patient selection procedure, the optimal stem cell selection protocol, the ideal injection number, and the safety of stem cell therapy. The purpose of this review is to summarize the available clinical studies and basic research related to stem cell therapy for ONFH.

show abstract

“…With regard to the effect of MSC differentiation on the cell surface profile of the cells, there are conflicting results presented in different studies. For example, Li et al describe an upregulation of HLA-DR on MSC after hepatocyte differentiation ( 30 ), while several other studies report no change in cell surface proteins after chondrogenic ( 31 ), myogenic ( 32 ), and insulin-producing cell ( 33 ) differentiation.…”

Section: Immunogenicity and Immunomodulatory Potential Of Allogeneic mentioning

confidence: 99%

Anti-Donor Immune Responses Elicited by Allogeneic Mesenchymal Stem Cells and Their Extracellular Vesicles: Are We Still Learning?

et al. 2017

View full text Add to dashboard Cite

Mesenchymal stromal cells (MSC) have been used to treat a broad range of disease indications such as acute and chronic inflammatory disorders, autoimmune diseases, and transplant rejection due to their potent immunosuppressive/anti-inflammatory properties. The breadth of their usage is due in no small part to the vast quantity of published studies showing their ability to modulate multiple immune cell types of both the innate and adaptive immune response. While patient-derived (autologous) MSC may be the safer choice in terms of avoiding unwanted immune responses, factors including donor comorbidities may preclude these cells from use. In these situations, allogeneic MSC derived from genetically unrelated individuals must be used. While allogeneic MSC were initially believed to be immune-privileged, substantial evidence now exists to prove otherwise with multiple studies documenting specific cellular and humoral immune responses against donor antigens following administration of these cells. In this article, we will review recent published studies using non-manipulated, inflammatory molecule-activated (licensed) and differentiated allogeneic MSC, as well as MSC extracellular vesicles focusing on the immune responses to these cells and whether or not such responses have an impact on allogeneic MSC-mediated safety and efficacy.

show abstract

Immunologic properties of differentiated and undifferentiated mesenchymal stem cells derived from umbilical cord blood

Cited by 18 publications

References 43 publications

Mesenchymal Stem Cell Therapy for Aging Frailty

Mesenchymal Stem Cell Therapy for Aging Frailty

Stem cell therapy for treating osteonecrosis of the femoral head: From clinical applications to related basic research

Anti-Donor Immune Responses Elicited by Allogeneic Mesenchymal Stem Cells and Their Extracellular Vesicles: Are We Still Learning?

Contact Info

Product

Resources

About